News Regeneron and Alnylam seek RNAi therapies for NASH Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement.
News Intercept shares dive after FDA safety alert on liver drug Regulator warns of death risk in patients on higher than recommended dose.
News Novo Nordisk board member quits over NASH conflict of intere... Mary Szela has quit to avoid a conflict of interest.
News Genfit encounters trial recruitment problem in hunt for NASH... Genfit was among a group of NASH companies publishing updates at the International Liver Congress.
News Novartis and Allergan to combine drugs in NASH Swiss pharma also aims for new CAR-T therapy indication.
Views & Analysis Novartis muscles into NASH fatty liver disease Company's Eric Hughes on what it takes to be leader in NASH - and what can be learnt from hepatitis C.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.